Financial Report: Pfizer

Pfizer

1Q Revenues: $13.0 billion (+20%)

1Q Earnings: $3.0 billion (+27%)

Comments: Innovative Product sales were $7.0 billion, up 23% driven by Eliquis globally, Lyrica and Xeljanz both primarily in the U.S., Enbrel in most international markets and Chantix primarily in the U.S. Global Vaccines sales were $1.6 billion, up 18%. Global Oncology revenues were $1.0 billion, up 90% driven by Ibrance for advanced breast cancer and, to a lesser extent, stronger demand for Sutent and Xalkori in most markets. Established Product sales were $6.0 billion, up 17%. In September 2015, Pfizer acquired Hospira, its legacy operations contributed $1.2 billion in sales in the quarter. Global Established Pharmaceutical segment sales were $4.8 billion, down 7% due to loss of exclusivity and associated generic competition for certain Peri-LOE Products, primarily Zyvox in the U.S. and certain developed Europe markets as well as Lyrica in certain developed Europe markets.